The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InProtalix BioTherapeutics and its partner Chiesi Global Rare Diseases announced that the European Commission has approved a new dosing regimen for pegunigalsidase alfa. The approval allows for a dosage of 2 mg/kg every four weeks for adult patients with Fabry disease who have stabilized on enzyme replacement therapy (ERT). This regulatory milestone has triggered a significant $25 million payment from Chiesi to Protalix, strengthening the company's financial position and balance sheet. The new schedule offers a more flexible treatment option compared to the standard bi-weekly dosing, potentially improving patient convenience and adherence. Analysts view this development as a positive catalyst for Protalix, as it expands the market reach of its therapy while providing immediate non-dilutive capital. The company continues to focus on enhancing treatment options for rare genetic disorders through its proprietary ProCellEx platform.